Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating restated by equities researchers at Peel Hunt in a note issued to investors on Thursday.
Several other brokerages have also weighed in on HIK. Citigroup lifted their price objective on Hikma Pharmaceuticals from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Barclays reissued an “underweight” rating on shares of Hikma Pharmaceuticals in a report on Monday, October 15th. Numis Securities lowered Hikma Pharmaceuticals to a “hold” rating and set a GBX 1,560 ($20.38) price objective for the company. in a report on Thursday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the stock a “neutral” rating in a report on Tuesday, November 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Hikma Pharmaceuticals has an average rating of “Hold” and an average target price of GBX 1,815.71 ($23.73).
Shares of HIK opened at GBX 1,704.50 ($22.27) on Thursday. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($10.64) and a fifty-two week high of GBX 2,346 ($30.65).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Recommended Story: What is dollar cost averaging (DCA)?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.